Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Approves Covid Vaccines from Two Companies, Sinocelltech and Clover

publication date: Dec 5, 2022

Two China biopharmas, Sinocelltech Group and Clover Biopharma, announced that their recombinant COVID-19 products were approved to launch under emergency rules. Shenzhou Cell Engineering, a unit of Beijing’s Sinocelltech, has developed a vaccine that showed efficacy against omicron strains BA.1 and BA.5 with potential use against future variants as well. Clover tested its candidate as an effective booster for people who had received two doses of an inactivated vaccine. At one point in 2021, GAVI, the UN vaccine alliance, had signed up to buy 414 million doses of the Clover vaccine booster. More details...

Stock Symbol: (SHA:688520)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital